Summary & Overview
HCPCS Level II J1598: Glycopyrrolate Injection, 0.1 mg
HCPCS Level II code J1598 denotes a 0.1 mg injection of glycopyrrolate (Fresenius Kabi), specified as not therapeutically equivalent to J1596. This designation matters nationally because HCPCS drug codes identify exact branded formulations and strengths for reimbursement, billing accuracy, and drug-specific utilization tracking. Precise coding affects payment, inventory management, and clinical documentation when alternative branded products are available. Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the clinical context for glycopyrrolate injections, typical sites of service where the drug is administered, and the importance of using the correct HCPCS Level II code for claims. The publication summarizes benchmarks for utilization and coverage patterns across major national payers, notes distinctions between branded formulations and other HCPCS codes for glycopyrrolate, and outlines relevant billing considerations such as service line classification and common modifiers used in practice. Where specific payer policy details or taxonomies are not provided in the input, the report notes that data is not available.
Billing Code Overview
HCPCS Level II code J1598 represents an injection of glycopyrrolate (Fresenius Kabi), 0.1 mg, specifically noted as not therapeutically equivalent to J1596. This code designates a specific branded formulation and dose used for anticholinergic indications where glycopyrrolate is indicated.
Service type: Injection / Parenteral drug administration
Typical site of service: Hospital outpatient, ambulatory infusion center, physician office, or other outpatient facility where parenteral medications are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric inpatient or outpatient with excessive secretions, hypersalivation, or chronic drooling related to neurodevelopmental disorders (for example, cerebral palsy), Parkinson disease, stroke sequelae, or during perioperative care where anticholinergic control of secretions is required. An ordering clinician (neurology, pediatric neurology, otolaryngology, anesthesiology, or hospital medicine) documents the indication, dosage, and route. Pharmacy prepares J1598 as an injectable formulation of glycopyrrolate (Fresenius Kabi) in 0.1 mg units; nursing administers intravenous or intramuscular injection per facility protocol. Common clinical workflow steps: medication order entry with indication and dose; allergy check and verification of appropriate concentration; informed consent when required; administration with monitoring for anticholinergic effects (tachycardia, dry mouth, urinary retention); documentation of lot number and administration time. If used in the ambulatory infusion setting, billing includes the HCPCS code J1598 with applicable site-of-service and any relevant modifiers for billing circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (standard) | Use when no special circumstance applies. |